Andalib Alireza, Doulabi Hassan, Najafi Mohamadreza, Tazhibi Mehdi, Rezaie Abbas
Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Immunol. 2011 Mar;8(1):1-10.
Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets.
This study was performed to measure chemokine receptor expression on CD4 T cells for evaluation of Th1/Th2 dominantly in IFN-β treated patients.
Flowcytometry was used to detect chemokine receptor expression on CD4 T cell population in PBMCs obtained from MS and healthy control groups. Twenty six MS patients participated in this study before and after IFN-β therapy and the same number of healthy individuals were included.
The percentage of lymphocytes was 41.28% ± 10.30% 2 in the blood of MS group compared with 36.88% ± 5.51% in the control group (p=0.017). The CD4+CXCR3+ cells were 18.86% ± 8.46% in healthy group, 30.78% ± 9.8% in pre-treated MS patients and 21.06% ± 9.23% in post-treated group (p<0.001). The CD4+CCR4+ cell subsets were 27.35% ± 10.15% in healthy group; 28.17% ± 8.9% in pre-treated group and 34.20% ± 8.96% in the post-IFN-β treatment group. The subset of CD4+CCR4+ was found to be dominant after IFN-β therapy in comparison with the control group (p<0.001). CD4+CCR5+ percentage was 1.24% ± 0.92% in the healthy people, 1.23% ± 0.71% in the MS patients and 0.76% ± 0.49% in post-treatment status (p=0.003). CD4+CCR3+ cell subsets were 0.62% ± 0.67% in control group, 0.28% ± 0.26% in the MS patients (p=0.022) and 0.39% ± 0.54% in IFN-β treated patients (p=0.334). An association was found for CXCR3 expression in pre- and post-treatment status (r=0.840, p<0.001) as well as for CCR4+ expression (r=0.712, p<0.001) in the same groups. The Th1 response was dominant in pre-treatment states, and then it shifted to a Th2 dominant state after IFN-β treatment.
We suggest that the chemokine receptor expression of Th1/Th2 cell subsets could be used for monitoring and the evaluation of the MS disease status.
Th1细胞优先表达CXCR3、CCR5和CCR6，而CCR3和CCR4主要由Th2细胞亚群表达。多发性硬化症（MS）是一种依赖Th1细胞的中枢神经系统慢性炎症性疾病，免疫调节细胞因子可改变这些淋巴细胞亚群的趋化因子表达模式。
本研究旨在检测IFN-β治疗患者CD4 T细胞上趋化因子受体的表达，以评估Th1/Th2优势情况。
采用流式细胞术检测来自MS组和健康对照组的外周血单核细胞（PBMC）中CD4 T细胞群体上趋化因子受体的表达。26例MS患者在IFN-β治疗前后参与了本研究，并纳入了相同数量的健康个体。
MS组血液中淋巴细胞百分比为41.28%±10.30%，而对照组为36.88%±5.51%（p=0.017）。健康组中CD4+CXCR3+细胞为18.86%±8.46%，MS患者治疗前为30.78%±9.8%，治疗后为21.06%±9.23%（p<0.001）。健康组中CD4+CCR4+细胞亚群为27.35%±10.15%；治疗前组为28.17%±8.9%，IFN-β治疗后组为34.20%±8.96%。与对照组相比，IFN-β治疗后CD4+CCR4+亚群占优势（p<0.001）。健康人CD4+CCR5+百分比为1.24%±0.92%，MS患者为1.23%±0.71%，治疗后状态为0.76%±0.49%（p=0.003）。对照组中CD4+CCR3+细胞亚群为0.62%±0.67%，MS患者为0.28%±0.26%（p=0.022），IFN-β治疗患者为0.39%±0.54%（p=0.334）。在治疗前和治疗后状态下发现CXCR3表达存在相关性（r=0.840，p<0.001），在同一组中CCR4+表达也存在相关性（r=0.712，p<0.001）。治疗前Th1反应占优势，IFN-β治疗后则转变为Th2占优势状态。
我们认为Th1/Th2细胞亚群的趋化因子受体表达可用于监测和评估MS疾病状态。
